Evolution of Biologic Therapies for the Treatment of Psoriasis
- 1 September 2003
- journal article
- research article
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 2 (5) , 286-294
Abstract
Over the past three decades, laboratory and clinical research findings have shown that T cells are the primary mediators of psoriasis pathogenesis and that psoriasis can be treated by eliminating these T cells or interfering with their activation or activity. Based on these observations, many new biologic therapies to treat psoriasis are now in development. These agents, developed primarily through recombinant DNA techniques, are designed to target T cells and the immunologic cascade associated with their activation. Four basic strategic approaches that focus on the steps involved in the immunopathology of psoriasis are: 1) elimination of the pathogenic T cells; 2) inhibition of T-cell activation, proliferation, and migration; 3) immune deviation to down-regulate the type 1 (TH1) response predominant in psoriasis; and 4) blockade of cytokine production. The goal of these new therapies is to improve the treatment of psoriasis, particularly moderate to severe disease, with agents that are well tolerated and safe for long-term use.Keywords
This publication has 42 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking.Journal of Investigative Dermatology, 2000
- Inflammatory Skin Diseases, T Cells, and Immune SurveillanceNew England Journal of Medicine, 1999
- Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesionsJournal of Clinical Investigation, 1999
- Lymphocyte Homing and HomeostasisScience, 1996
- T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell ProfilesCritical Reviews in Immunology, 1995
- DAB486IL‐2 (IL‐2 Toxin) Selectively Inactivates High‐Affinity IL‐2 Receptor‐Bearing Human Peripheral Blood Mononuclear CellsAnnals of the New York Academy of Sciences, 1991
- Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigationsArchives of Dermatology, 1990
- Predominance of ?memory? T cells (CD4+, CDw29+) over ?naive? T cells (CD4+, CD45R+) in both normal and diseased human skinArchives of Dermatological Research, 1989